Radar›Companies›Biological Products, Excluding Disgnostic Substances Stocks in USA: Prism Readiness Cohort 2
United States biological products, excluding disgnostic substances industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Biological Products, Excluding Disgnostic Substances Stocks in USA: Prism Readiness Cohort 2

A five-company biological products, excluding disgnostic substances cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness
Readiness leaderDyadic · 57
Strongest available pathKrystal Biotech · +596.9%
Widest latest marginKrystal Biotech · 52.6%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1DYAI · Nasdaq

Dyadic

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1979Jupiter, Florida$21.3M market cap
View full Companies Radar profile
57Moderate
Snapshot price$0.53as of page date
Monthly-close return-90.4%five-year window
FY2025 revenue$0.00BDYADIC INTERNATIONAL INC
Net margin-238.3%FY2025
Prism attention1.7%share across these five
Filing track recordRevenue, USD billions
+28.6%
$0$0.0B$0.0B$0.0BFY2021: $0.002BFY2022: $0.003BFY2023: $0.003BFY2024: $0.003BFY2025: $0.003B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 6.5%
52-week position2% through range
$0.51$1.60
News mentions909
Community mentions0partial coverage
U.S.-scope patents133
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal83/100
Management stability90/100
Market position6/100
Capital-event signal80/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 4 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2NBIX · Nasdaq

Neurocrine

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1992San Diego, California$15.93B market cap
View full Companies Radar profile
57Moderate
Snapshot price$156.8as of page date
Monthly-close return+63.4%five-year window
FY2025 revenue$2.86BNEUROCRINE BIOSCIENCES INC
Net margin16.7%FY2025
P/E snapshot22.9xone ratio, not a verdict
Prism attention5.1%share across these five
Filing track recordRevenue, USD billions
+152.4%
$0$1.0B$1.9B$2.9BFY2021: $1.133BFY2022: $1.489BFY2023: $1.887BFY2024: $2.355BFY2025: $2.861B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 26.0%
52-week position54% through range
$122.1$186.1
News mentions2.8K
Community mentions0partial coverage
U.S.-scope patents1228
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal79/100
Management stability90/100
Market position8/100
Capital-event signal70/100
Innovation pulse15/100
Management signal

No leadership-churn flag in the model; 3 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 4 M&A involvements, 0 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 6 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3AMGN · Nasdaq

Amgen

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1980WILMINGTON$236.86B market cap
View full Companies Radar profile
54Moderate
Snapshot price$438.1as of page date
Monthly-close return+106.0%five-year window
FY2025 revenue$36.75BAMGEN INC
Net margin21.0%FY2025
P/E snapshot27.2xone ratio, not a verdict
Prism attention89.6%share across these five
Filing track recordRevenue, USD billions
+41.5%
$0$12.3B$24.5B$36.8BFY2021: $25.979BFY2022: $26.323BFY2023: $28.190BFY2024: $33.424BFY2025: $36.751B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 9.1%
52-week position95% through range
$269.8$447.0
News mentions48.5K
Community mentions2.2Kpartial coverage
U.S.-scope patents21491
Prism Insights

What sits behind the readiness signal

Observed risk 9/100higher means more observed risk
Earnings signal70/100
Management stability90/100
Market position52/100
Capital-event signal50/100
Innovation pulse15/100
Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 70 M&A involvements, 15 asset-acquisition events and 15 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 2 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4KRYS · Nasdaq

Krystal Biotech

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2015Pittsburgh, Pennsylvania$10.77B market cap
View full Companies Radar profile
54Moderate
Snapshot price$363.8as of page date
Monthly-close return+596.9%five-year window
FY2025 revenue$0.39BKrystal Biotech, Inc.
Net margin52.6%FY2025
P/E snapshot45.6xone ratio, not a verdict
Prism attention1.9%share across these five
Filing track recordRevenue, USD billions
+667.5%
$0$0.1B$0.3B$0.4BFY2023: $0.051BFY2024: $0.291BFY2025: $0.389B202320242025
FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 177.0%
52-week position92% through range
$136.7$382.5
News mentions1.0K
Community mentions0partial coverage
U.S.-scope patents172
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal83/100
Management stability90/100
Market position0/100
Capital-event signal67/100
Innovation pulse5/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5STRO · NASDAQ

Sutro Biopharma

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2003San Francisco, California$345.2M market cap
View full Companies Radar profile
54Moderate
Snapshot price$20.82as of page date
Monthly-close return-89.0%five-year window
FY2025 revenue$0.10BSUTRO BIOPHARMA, INC.
Net margin-186.5%FY2025
P/E snapshot-3.4xone ratio, not a verdict
Prism attention1.7%share across these five
Filing track recordRevenue, USD billions
+65.6%
$0$0.1B$0.1B$0.2BFY2021: $0.062BFY2022: $0.068BFY2023: $0.154BFY2024: $0.062BFY2025: $0.102B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 13.4%
52-week position37% through range
$7.15$43.85
News mentions916
Community mentions0partial coverage
U.S.-scope patents469
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal82/100
Management stability90/100
Market position0/100
Capital-event signal64/100
Innovation pulse15/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Krystal Biotech
+596.9%
Amgen
+106.0%
Neurocrine
+63.4%
Sutro Biopharma
-89.0%
Dyadic
-90.4%

Latest revenue

USD billions, official filing scope shown on each company card.

Amgen
$36.75B
Neurocrine
$2.86B
Krystal Biotech
$0.39B
Sutro Biopharma
$0.10B
Dyadic
$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Krystal Biotech
52.6%
Amgen
21.0%
Neurocrine
16.7%
Sutro Biopharma
-186.5%
Dyadic
-238.3%

Prism news attention

Normalized share across these five names; attention is not quality.

Amgen
89.6%
Neurocrine
5.1%
Krystal Biotech
1.9%
Dyadic
1.7%
Sutro Biopharma
1.7%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized biological products, excluding disgnostic substances news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Amgen leads the conversation

It holds 89.6% of measured biological products, excluding disgnostic substances news attention and also carries the basket's largest revenue base at $36.75B.

Price path

Krystal Biotech leads the available price paths

Its monthly-close return is +596.9% for the five-year window. At the other end, Dyadic is -90.4% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Krystal Biotech has the widest latest margin

Its FY2025 net margin is 52.6%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Sutro Biopharma shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -3.4x while its five-year window price return is -89.0%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · DYAI

Dyadic

909available Prism news records

Prism top themes

Earnings & financial performance
20
Price action & investor response
12
Leadership & governance
8

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+7.8%110 latest 12m vs 102 prior 12m
2024-01: 9 mentions2024-02: 15 mentions2024-03: 17 mentions2024-04: 4 mentions2024-05: 11 mentions2024-06: 11 mentions2024-07: 11 mentions2024-08: 4 mentions2024-09: 5 mentions2024-10: 5 mentions2024-11: 9 mentions2024-12: 0 mentions2025-01: 6 mentions2025-02: 43 mentions2025-03: 11 mentions2025-04: 3 mentions2025-05: 3 mentions2025-06: 2 mentions2025-07: 7 mentions2025-08: 11 mentions2025-09: 3 mentions2025-10: 16 mentions2025-11: 13 mentions2025-12: 9 mentions2026-01: 8 mentions2026-02: 9 mentions2026-03: 16 mentions2026-04: 8 mentions2026-05: 9 mentions2026-06: 1 mentions2024-012026-06

Machine-classified coverage tone

89.1% positive-2.8 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

vaccine formulation 13diagnostic biotechnology 11subunit vaccines 11synthetic biology 10viral vector vaccines 10enzyme engineering 9mrna vaccines 8investigational new vaccine 7

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-12 · trend and themes shown through 2026-06
Areas of research · NBIX

Neurocrine

2,766available Prism news records

Prism top themes

Price action & investor response
127
Capital allocation & transactions
103
Earnings & financial performance
46
Legal, arbitration & regulatory
45
Leadership & governance
24

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-28.1%512 latest 12m vs 712 prior 12m
2024-01: 18 mentions2024-02: 34 mentions2024-03: 16 mentions2024-04: 35 mentions2024-05: 66 mentions2024-06: 17 mentions2024-07: 18 mentions2024-08: 58 mentions2024-09: 27 mentions2024-10: 16 mentions2024-11: 22 mentions2024-12: 21 mentions2025-01: 45 mentions2025-02: 338 mentions2025-03: 40 mentions2025-04: 34 mentions2025-05: 70 mentions2025-06: 23 mentions2025-07: 17 mentions2025-08: 10 mentions2025-09: 13 mentions2025-10: 22 mentions2025-11: 22 mentions2025-12: 22 mentions2026-01: 59 mentions2026-02: 47 mentions2026-03: 23 mentions2026-04: 212 mentions2026-05: 53 mentions2026-06: 12 mentions2024-012026-06

Machine-classified coverage tone

93.3% positive+5.7 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

ssri effectiveness trials 49treatment-resistant depression studies 37gene therapy rare diseases 36antipsychotic metabolic effects 33antidepressant response rates 30stock price 25depression treatment outcomes 24psychotropic adverse reactions 21

Keyword tag occurrences in available Prism news records.

Coverage: 2010-02-04–2026-06-19 · trend and themes shown through 2026-06
Areas of research · AMGN

Amgen

48,476available Prism news records

Prism top themes

Price action & investor response
929
Macro demand & rates
917
Earnings & financial performance
569
Capital allocation & transactions
458
Legal, arbitration & regulatory
452

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-26.7%5,347 latest 12m vs 7,297 prior 12m
2024-02: 389 mentions2024-03: 387 mentions2024-04: 316 mentions2024-05: 671 mentions2024-06: 266 mentions2024-07: 272 mentions2024-08: 379 mentions2024-09: 332 mentions2024-10: 318 mentions2024-11: 445 mentions2024-12: 312 mentions2025-01: 361 mentions2025-02: 3,327 mentions2025-03: 462 mentions2025-04: 359 mentions2025-05: 380 mentions2025-06: 296 mentions2025-07: 326 mentions2025-08: 391 mentions2025-09: 554 mentions2025-10: 374 mentions2025-11: 447 mentions2025-12: 507 mentions2026-01: 504 mentions2026-02: 770 mentions2026-03: 400 mentions2026-04: 688 mentions2026-05: 513 mentions2026-06: 198 mentions2026-07: 1 mentions2024-022026-07

Machine-classified coverage tone

83.1% positive+0.5 pp vs preceding four quarters
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

generic drug approval 443biosimilar approval 308stock performance 267biosimilar efficacy 256biosimilar market entry 249regulatory pathway biosimilars 200angiogenesis inhibitors 169gene therapy rare diseases 148

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-07-10 · trend and themes shown through 2026-07
Areas of research · KRYS

Krystal Biotech

1,006available Prism news records

Prism top themes

Price action & investor response
105
Capital allocation & transactions
55
Earnings & financial performance
39
Legal, arbitration & regulatory
15
Leadership & governance
6

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+65.2%294 latest 12m vs 178 prior 12m
2024-01: 6 mentions2024-02: 40 mentions2024-03: 7 mentions2024-04: 19 mentions2024-05: 20 mentions2024-06: 8 mentions2024-07: 4 mentions2024-08: 15 mentions2024-09: 9 mentions2024-10: 5 mentions2024-11: 12 mentions2024-12: 9 mentions2025-01: 13 mentions2025-02: 36 mentions2025-03: 16 mentions2025-04: 31 mentions2025-05: 15 mentions2025-06: 13 mentions2025-07: 14 mentions2025-08: 33 mentions2025-09: 28 mentions2025-10: 30 mentions2025-11: 13 mentions2025-12: 17 mentions2026-01: 29 mentions2026-02: 45 mentions2026-03: 15 mentions2026-04: 30 mentions2026-05: 36 mentions2026-06: 4 mentions2024-012026-06

Machine-classified coverage tone

93.1% positive+1.4 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 43stock price 39biotech incubator 32gene therapy rare diseases 31stock surge 15share price 12company valuation 11stock movement 11

Keyword tag occurrences in available Prism news records.

Coverage: 2016-02-01–2026-06-13 · trend and themes shown through 2026-06
Areas of research · STRO

Sutro Biopharma

916available Prism news records

Prism top themes

Capital allocation & transactions
17
Price action & investor response
17
Legal, arbitration & regulatory
13
Earnings & financial performance
10
Leadership & governance
10

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-12.7%117 latest 12m vs 134 prior 12m
2024-01: 1 mentions2024-02: 11 mentions2024-03: 6 mentions2024-04: 28 mentions2024-05: 18 mentions2024-06: 6 mentions2024-07: 9 mentions2024-08: 5 mentions2024-09: 20 mentions2024-10: 7 mentions2024-11: 16 mentions2024-12: 4 mentions2025-01: 8 mentions2025-02: 15 mentions2025-03: 26 mentions2025-04: 12 mentions2025-05: 8 mentions2025-06: 4 mentions2025-07: 2 mentions2025-08: 6 mentions2025-09: 10 mentions2025-10: 3 mentions2025-11: 11 mentions2025-12: 21 mentions2026-01: 7 mentions2026-02: 14 mentions2026-03: 19 mentions2026-04: 12 mentions2026-05: 11 mentions2026-06: 1 mentions2024-012026-06

Machine-classified coverage tone

90.8% positive-1.6 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

adc therapeutics 56cancer biomarkers 18stock price 10stock performance 9angiogenesis inhibitors 8share price 7stock surge 5vaccine candidate selection 5

Keyword tag occurrences in available Prism news records.

Coverage: 2010-11-17–2026-06-11 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

AMGN

Amgen

2,234 mentions
Stock and valuation
696
Products, pricing and logistics
516
Workplace and hiring
240
Other company context
4

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 2,234 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

DYAI

Dyadic

through 2025-08-05
Earnings releases 5Company announcements 1Listing / IPO 1
  1. Earnings releases

    Dyadic International, Inc. (Nasdaq: DYAI) ... today announced that it will report its financial results for the second quarter 2025.

  2. Listing / IPO

    Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced the pricing of its previously announced underwritten public offering of 6,052,000 shares of common stock at a public offering price of $0.95 per share.

  3. Company announcements

    In March 2024, the company released its financial results for the fiscal year 2023, with the company reporting revenues of $2,899,000

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

NBIX

Neurocrine

through 2026-04-12
Earnings releases 50Leadership changes 7Company announcements 6Business contracts 3Listing / IPO 3
  1. M&A

    Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has agreed to acquire Soleno Therapeutics, Inc. (NASDAQ: SLNO) for $53.00 per share in cash, valuing the target at about $2.9 billion.

  2. Company announcements

    Gano said Ingrezza, now in its eighth year of commercialization, produced $2.51 billion in 2025 revenue, up about 9% year over year, with “double‑digit volume growth” and record new prescriptions (NRX) across multiple quarters.

  3. Leadership changes

    SAN DIEGO , March 17, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief Technical Operations Officer.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

AMGN

Amgen

through 2026-04-29
Earnings releases 43Lawsuits 23Regulatory 17Company announcements 14Leadership changes 8
  1. Regulatory

    First up, the agency has requested—again—that Amgen remove the autoimmune therapy Tavneos from the market. Specifically, the FDA says that unblinded study personnel manipulated results of the pivotal clinical trial that supported the drug’s approval to make it look more effective.

  2. Earnings releases

    Amgen delivered strong performance in 2025, with double‑digit growth in revenues and earnings per share.

  3. Leadership changes

    Katie Casey was promoted to director of corporate affairs for obesity and related conditions communications at Amgen.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

KRYS

Krystal Biotech

through 2026-05-04
Earnings releases 32Leadership changes 2Listing / IPO 2Company announcements 1Regulatory 1
  1. Earnings releases

    Romano reported net income of $55.9 million for the quarter, or $1.91 per basic share and $1.83 per diluted share, compared to net income of $35.7 million a year earlier.

  2. Listing / IPO

    Krystal Biotech Inc., of Pittsburgh, closed its previously announced public offering of 3.45 million shares, including the underwriters' fully exercised option to purchase 450,000 shares, at $20 per share, grossing the company $69 million.

  3. Regulatory

    Despite obtaining FDA approval for treating Dystrophic Epidermolysis Bullosa (DEB), there’s no guarantee of similar regulatory green lights elsewhere, which casts a shadow on their operational outcomes.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

STRO

Sutro Biopharma

through 2026-03-23
Company announcements 8Earnings releases 5Leadership changes 4Regulatory 4Business contracts 1
  1. Earnings releases

    Revenue was $102.5 million for the year ended December 31, 2025.

  2. Regulatory

    On December 17, 2025, the Company received confirmation from the Listing Qualifications Department of Nasdaq that as of December 16, 2025 the Company’s common stock has maintained an average closing share price of at least $1.00 following the Company’s 1:10 reverse stock split that became effective on December 3, 2025. The Company’s shares are no longer considered to be below the minimum bid price requirement of Rule 5450(a)(1), and as a result the Company has regained compliance with the Nasdaq continued listing standard.

  3. Company announcements

    Sutro Biopharma, Inc. (NASDAQ: STRO) confirmed on Monday that it will undergo a significant restructuring process designed to extend its cash runway through at least the middle of 2027.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Biological Products, Excluding Disgnostic Substances Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary biological products, excluding disgnostic substances news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

biologics market

26 sources67.0% extraction confidence
2020 extracted base$194.20B–$477.15B
2033 extracted forecast$685.30B–$1.37T
Implied source CAGR8.5%
high demand for the treatment of different disease indicationsTechnologyadvancements in biotechnology

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, North America, Mexico. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Biological Products, Excluding Disgnostic Substances news pulse

24,998available Prism news records
Latest 12m volume+9.8%10786 vs 9825 records
Positive classified tone41.7%+4.6 pp vs prior four quarters
2024-01: 892 mentions2024-02: 804 mentions2024-03: 821 mentions2024-04: 790 mentions2024-05: 1,080 mentions2024-06: 758 mentions2024-07: 563 mentions2024-08: 879 mentions2024-09: 628 mentions2024-10: 779 mentions2024-11: 620 mentions2024-12: 655 mentions2025-01: 712 mentions2025-02: 1,067 mentions2025-03: 1,362 mentions2025-04: 999 mentions2025-05: 803 mentions2025-06: 593 mentions2025-07: 966 mentions2025-08: 3,062 mentions2025-09: 751 mentions2025-10: 687 mentions2025-11: 634 mentions2025-12: 660 mentions2026-01: 312 mentions2026-02: 1,077 mentions2026-03: 634 mentions2026-04: 1,323 mentions2026-05: 87 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching biological, disgnostic, excluding, substance, biologic. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

harm reduction strategies
4,078
substance abuse education
3,736
opioid addiction and treatment
3,643
overdose prevention techniques
3,482
controlled substance regulations
3,381
substance abuse overdose fatalities
3,287

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

mind-altering drug consumption 1,795opioid diversion abuse 1,702fentanyl treatment programs 1,649drug overdose 1,576cannabis policy reform discussions 1,328psychedelic mental health studies 1,328medication-assisted treatment opioids 1,265psychoactive drug intake 1,170

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

high demand for the treatment of different disease indications

26 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

harm reduction strategies

4,078 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

2,049 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

Biosimilars entering the market

1,542 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+9.8% news volume

The latest 12 months contain 10,786 matched records versus 9,825 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

41.7% positive · +4.6pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2836 (Biological Products, Excluding Disgnostic Substances), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 6–13. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Biological Products, Excluding Disgnostic Substances Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

Dyadic has the widest attention-readiness rank gap

It ranks #4 by measured news attention (1.7%) and #1 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Dyadic in Companies Radar

Sutro Biopharma shows a price-operating divergence to inspect

Its displayed filing-revenue change is +65.6% while its available monthly-close return is -89.0%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Sutro Biopharma in Companies Radar
Explanations

Attention measures coverage volume, not quality

Amgen's 89.6% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Amgen in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Dyadic's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 57/100 score.

Open Dyadic in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon